2025.09.19
On September 18, 2025, Sichuan Biokin Pharmaceutical Co., Ltd. (Biokin, 688506.SH) disclosed its report on the issuance of shares to specific targets. The total amount of funds raised was RMB 3.764 billion, and JunHe served as the issuer's legal counsel for this project. All the funds raised will be used for innovative drug research and development projects, which will help Biokin expand the depth and breadth of its product pipeline under development, consolidate its competitive advantage in the field of oncology treatment, and provide strong support for achieving the company's strategic goals.
Deal Highlights
This transaction took 110 days from acceptance to registration, making it the largest A-share equity financing project in the healthcare industry since the implementation of the comprehensive registration system. It was an A-share refinancing project with the smallest discount rate in the healthcare industry this year.
Biokin was established in 2006 in Chengdu, Sichuan Province, China, and was listed on the STAR Market in January 2023. It is a comprehensive biopharmaceutical company focused on biomedicine and addressing unmet clinical needs, and it has capabilities in early global research and development, global clinical development, large-scale production and commercialization. Biokin has established R&D centers in both China and the United States and has built core technology platforms such as the innovative ADC drug development platform (HIRE-ADC platform) and the multi-specific antibody development platform (GNC platform), while developing a pipeline of advanced drugs. It also has business segments in chemical drug and traditional Chinese medicine formulations, forming full industry chain operation capabilities. Biokin has a strategy of being "rooted in China, going global and becoming a multinational pharmaceutical company (MNC)" and is committed to maintaining its leading advantage in the field of oncology drugs.
JunHe has provided legal services to Biokin since 2020, including its listing on the STAR Market, and serves as the company's legal advisor. In this transaction, JunHe acted as the issuer's counsel, fully leveraging its professional service capabilities. With close cooperation from Biokin and other intermediaries, JunHe completed the demonstration of the issuance plan, undertook legal due diligence, prepared the application materials and responded to regulatory inquiries in a short time period. We assisted Biokin in successfully passing the review of the Shanghai Stock Exchange and completing the registration with the China Securities Regulatory Commission, taking only 110 days from acceptance to registration. JunHe's consistently rigorous and efficient work style, meticulous and dedicated service attitude, and professional and high-quality service won unanimous recognition and trust from Biokin and other intermediaries.
The partners leading this transaction were ZHANG, Tao, TAO, Xudong, MA, Rui and LIU, Yunlong. ZHAO, Jikui was the internal review partner.
